With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

For the full year 2024, BTCS reported revenue of $4.1 million, up a record 204% from $1.3 million for 2023. For the fourth quarter, revenue of $2.3 million was up 612% from a year ago and 214% higher ...

The famous Twitter' bird l o go' sign that once adorned the company's Market Square headquarters in San Francisco has sold ...